Insulin and atherosclerosis: villain, accomplice, or innocent bystander?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: A link between hypertension, obesity and glucose intolerance. J Clin Invest 1985;75:809-17.
Abbott WG, Lillioja S, Young AA, et al. Relationships between plasma lipoprotein concentrations and insulin action in an obese hyperinsulinemic population. Diabetes 1987;36:897-904. Editonial
Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl 7Med 1989;320:702-6.
DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDD, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
Logan RL, Reimesma RA, Thomson M, et al. Risk factors for ischaemic heart-disease in normal men aged 40: Edinburgh-Stockholm Study. Lancet 1978;i:949-52.
McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991;337:382-6.
Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:131-41.
Ducimentiere P, Eschwege R, Papoz L, et al. Relationship of plasma insulin level to the incidence of myocardial infarction and coronary heart disease. Diabetologia 1980;19:205-10.
Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-60.
Cullen K, Stenhouse NS, Wearne KL, et al. Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia-13-year study. J Chron Dis 1983;36: 371-7.
Hargreaves AD, Logan RL, Elton RA, et al. Glucose tolerance, plasma insulin, HDL cholesterol and obesity: 12-year follow-up and development of coronary heart disease in Edinburgh men. Atherosclerosis 1992;94:61-9.
Welin L, Eriksson H, Larsson B, et al. Hyperinsulinemia is not a major coronary risk factor in elderly men: The study of men born in 1913. Diabetologia 1992;35:766-70.
Liu QZ, Knowler WC, Nelson RG, et al. Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians: cross-sectional and prospective analyses. Diabetes 1992;41: 1141-50.
Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl _Med 1987;317:350-7.
Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990;39: 167-74.
Saad MF, Lillioja S, Nyomba BL, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991;324:733-9.
Manolio TA, Savage PJ, Burke GL, et al. Association of fasting insulin with blood pressure and lipids in young adults: The CARDIA Study Arteriosclerosis 1990;10:430-6.
Cruickshank JK, Cooper J, Burnett M, et al. Ethnic difference in fasting plasma C-peptide and insulin in relation to glucose tolerance and blood pressure. Lancet 1991;338:842-7.
Haffner SM, Fong D, Hazuda HP, et al. Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism 1988;37:338-45.
Collins VR, Dowse GK, Finch CF, et al. An inconsistent relationship between insulin and blood pressure in three Pacific island populations. J Clin Epidemiol 1990;43:1369-78.
Cigolini M, Seidell JC, Charzewska J, et al. Fasting serum insulin in relation to fat distribution, serum lipid profile, and blood pressure in European women: The European Fat Distribution Study. Metabolism 1991;40:781-7.
Muller DC, Elahi D, Pratley RE, et al. An epidemiologic test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 1993;76:544-8.
Modan M, Or J, Karaski A, et al. Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease. Circulation 1991;84: 1165-75.
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long term benefit with niacin. Y Am Coll Cardiol 1986;8:1245-55.
Kahn SE, Beard JC, Schwartz MW, et al. Increased fl-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989;38:562-8.
The University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1982;31(suppl5): 1-77.
Frayn KN, Coppack SW. Insulin resistance, adipose tissue and coronary heart disease. Clin Sci 1992;82:1-8.
Laakso M, Edelman SV, Brechtel G, et al. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men: a novel mechanism for insulin resistance. J Clin Invest 1990;85:1844-52.
Juhan-Vague I, Vague P. Hypofibrinolysis and insulin resistance. Diabetes Metab 1991;17:96-100.
Brindley DN, Rolland Y. Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis. Clin Sci 1989;77:453-61.
Karam JH. Type II diabetes and syndrome X: pathogenesis and glycemic management. Endocrinol Metab Clin North Am 1992;21:329-50.
Eriksson KF, Lindgarde F, Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetlogia 1991;34:891-8 37 National High Blood Pressure Education Program (US). The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 1993; 153:149-52.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
Widen EIM, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992;41:354-8.
Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of a new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-5.
Fulcher GR, Walker M, Catalano C, et al. Overnight suppression of lipolysis with acipimox increases carbohydrate oxidation and lowers fasting blood glucose in type 2 (non-insulin dependent) diabetes [abstr]. Diabetologia 1989;32:489.